IBI343
Sponsors
Innovent Biologics (Suzhou) Co. Ltd., Zhejiang University, Ruijin Hospital
Conditions
Advanced Pancreatic CancersBorderline Resectable Pancreatic AdenocarcinomaGastric CancerLocally Advanced Unresectable or Metastatic Solid TumorsPancreatic CancerUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
RecruitingNCT05458219
Start: 2022-10-26End: 2027-12-31Target: 470Updated: 2025-11-07
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
RecruitingNCT07025889
Start: 2025-06-02End: 2028-06-30Target: 55Updated: 2025-06-18
Phase 2
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
RecruitingNCT06770439
Start: 2025-04-18End: 2028-01-31Target: 64Updated: 2025-09-23
IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
Not yet recruitingNCT07415525
Start: 2026-02-01End: 2030-12-31Target: 40Updated: 2026-02-17
Phase 3
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma
RecruitingNCT06238843
Start: 2024-06-30End: 2027-12-31Target: 450Updated: 2025-08-24
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
RecruitingNCT07066098
Start: 2025-08-04End: 2028-06-30Target: 201Updated: 2025-08-15